Question-and-Answer Session
Operator
Thank you, sir. (Operator instructions) We will have our first question from Tom Russo with Baird.
Thomas Russo – Robert W. Baird
Good afternoon, thanks for taking the question. Mike, a couple of financial questions. You mentioned, I think - Rick mentioned the company’s goal - stretch goal of getting HAP approval this year, but I don’t think you mentioned a potential milestone that be associated with that. And also then you could please comment then what that milestone would be and also whether that R&D reimbursement that we saw in the fourth quarter, is that the kind of thing that might recur again from time-to-time?
Michael W. Aguiar
Sure, with regard to the HAP approval milestone, we haven’t disclosed that yet. So, I would just say stay tuned on that we will potentially update that as we get a little closer to, where we are with regard to the regulatory status. With regard to the reimbursement we received from Astellas, there is a certain portion of expenses that are reimbursable is possible that there could be some small additional dollars that are reimbursed, but it will not be extensive looking forward.
Thomas Russo – Robert W. Baird
And then can you also share what your current assumption is regarding another FDA panel for HAP and why you would either expect it or not expect it?
Rick E. Winningham
Yeah Tom, this is Rick Winningham. I mean, our operating assumption is that, we’re hopeful that we would another Advisory Committee Meeting to review Telavancin for Hospital-Acquired Pneumonia and, the basis for that is it’s just generally seems to be the way the anti-infective division that is going with regard to review of products.
Michael W. Aguiar
Yeah Tom, so just quickly, I think looking forward here, we would not be surprised that there is some sort of a HAP panel that happens that potentially could be, an industry level panel where certain they are discussed with regard to the treatment of the disease similar to what’s happen in the other indications that be number one. Number two, we did request a prior to review with our HAP application. However, we are guiding folks to assume a standard review and that within that standard review it’s highly likely we think that there will be a panel because as Rick said it seems to be the way FDA treating that today because as Rick said it seems to be the way, FDA is treating that today. So, I think that’s probably our most recent guidance with regard to how to think about HAP and our regulatory position.
- To read the full transcript on Seeking Alpha, click here »
